Role of nuclear factor-κB in melanoma

Por Amiri, Katayoun I., Richmond, Ann
Publicado em 2005

BMS-345541Targets Inhibitor of κB Kinase and Induces Apoptosis in Melanoma: Involvement of Nuclear Factor κB and Mitochondria Pathways

Por Yang, Jinming, Amiri, Katayoun I., Burke, James R., Schmid, Johannes A., Richmond, Ann
Publicado em 2006

A Phase I Trial of Bortezomib with Temozolomide in Patients with Advanced Melanoma: Toxicities, Antitumor Effects, and Modulation of Therapeutic Targets

Por Su, Yingjun, Amiri, Katayoun I., Horton, Linda W., Yu, Yingchun, Ayers, Gregory D., Koehler, Elizabeth, Kelley, Mark C., Puzanov, Igor, Richmond, Ann, Sosman, Jeffrey A.
Publicado em 2009

Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group

Por Ciombor, Kristen K., Feng, Yang, Benson, Al Bowen, Su, Yingjun, Horton, Linda, Short, Sarah P., Kauh, John Sae Wook, Staley, Charles, Mulcahy, Mary, Powell, Mark, Amiri, Katayoun I., Richmond, Ann, Berlin, Jordan
Publicado em 2014

Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence

Por Liu, Yan, Hawkins, Oriana E, Su, Yingjun, Vilgelm, Anna E, Sobolik, Tammy, Thu, Yee-Mon, Kantrow, Sara, Splittgerber, Ryan C, Short, Sarah, Amiri, Katayoun I, Ecsedy, Jeffery A, Sosman, Jeffery A, Kelley, Mark C, Richmond, Ann
Publicado em 2013

RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors

Por Su, Yingjun, Vilgelm, Anna E., Kelley, Mark C., Hawkins, Oriana E., Liu, Yan, Boyd, Kelli L., Kantrow, Sara, Splittgerber, Ryan C., Short, Sarah P., Sobolik, Tammy, Zaja-Milatovic, Snjezana, Dahlman, Kimberly Brown, Amiri, Katayoun I., Jiang, Aixiang, Lu, Pengcheng, Shyr, Yu, Stuart, Darrin D., Levy, Shawn, Sosman, Jeffrey A., Richmond, Ann
Publicado em 2012